China Pharma Holdings (CPHI) Net Income towards Common Stockholders: 2009-2025
Historic Net Income towards Common Stockholders for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.
- China Pharma Holdings' Net Income towards Common Stockholders rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
- Latest data reveals that China Pharma Holdings reported Net Income towards Common Stockholders of -$651,482 as of Q3 2025, which was down 23.30% from -$528,367 recorded in Q2 2025.
- In the past 5 years, China Pharma Holdings' Net Income towards Common Stockholders registered a high of -$475,976 during Q1 2023, and its lowest value of -$1.4 million during Q2 2024.
- Its 3-year average for Net Income towards Common Stockholders is -$889,146, with a median of -$785,572 in 2025.
- Per our database at Business Quant, China Pharma Holdings' Net Income towards Common Stockholders tumbled by 6,418.56% in 2021 and then spiked by 63.26% in 2025.
- China Pharma Holdings' Net Income towards Common Stockholders (Quarterly) stood at -$980,719 in 2021, then decreased by 28.90% to -$1.3 million in 2022, then climbed by 2.53% to -$1.2 million in 2023, then rose by 0.63% to -$1.2 million in 2024, then soared by 41.72% to -$651,482 in 2025.
- Its Net Income towards Common Stockholders was -$651,482 in Q3 2025, compared to -$528,367 in Q2 2025 and -$785,572 in Q1 2025.